ABCEFGHIJKLMNOPQRSTUVWXYZAAABACAD
1
Generic NameMDCNEMLCategoryIndicationsPrescribing RestrictionsDosageHTARHSELHSGBHSISHAHSASHTPNHCJHBTGHTKHKKBHTAJHOAGPKD KLANGPKD PETALINGPKD GOMBAKPKD HULU LANGATPKD KUALA LANGATPKD KUALA SELPKD HULU SELPKD S.BERNAMPKD SEPANG
2
2-deoxy-2-[18F] fluoro-D-glucose [18F] FDG InjectionV09IX04-000-P30-02-XXXNoA*Indicated for positron emission tomography (PET) imaging in the following setting: i. Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer ii. Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. iii. Neurology: For the identification of regions of abnormal glucose metabolism associated with foci or epileptic seizuresTo be prescribed by Nuclear Medicine Specialist onlyThe recommended dose is 6 Mbq/kg (0.162 mCi/kg). Example, for an adult with a body weight of 70 kg, the recommended dose is 420 Mbq (11 mCi)
3
Abacavir Sulphate 300mg tabletJ05AF06-183-T10-01-XXXYesA*Antiretroviral combination therapy of HIV infection in adults and adolescents from 12 years of age.i. Patients unsuitable or failed other HAART treatment ii. Patients who have renal impairment (CrCl < 50ml/min) when Abacavir and Lamivudine fixed-dose combination is not recommendedAdult: 300mg twice daily or 600mg daily Children: i. Weighing 14 to <20kg: one-half of a scored abacavir tablet twice daily ii. Weighing ≥20kg to <25kg: one-half of a scored abacavir tablet in the morning and one whole tablet in the evening iii. Weighing at least 25kg: according to adult dose
4
Abacavir Sulphate 600mg and Lamivudine 300mg TabletJ05AR02-964-T10-01-XXXYesA*Antiretroviral combination therapy of HIV infection in adults and adolescents from 12 years of age with the following criteria: i)Patients unsuitable or failed other HAART treatment. ii)Patients who are at high risk of renal impairment. iii)Patients with osteoporosis or at high risk of bone loss.NoneADULTS & ADOLESCENT (> 12 years of age): Recommended dose is one tablet once daily. Not to be used in adults or adolescents weigh less than 40kg. CHILDREN : Not recommended
5
Abemaciclib 100mg Film Coated TabletsL01XE50-000-T32-02-xxxNoA*Abemaciclib, in combination with endocrine therapy, is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.i. For high-risk stage II and III early breast cancer. High risk defined by clinical and pathological features: either ≥pALN (positive axillary lymph nodes) or 1 – 3 pALN and at least one of the following criteria: tumour size ≥5cm or histological grade 3. ii. To be prescribed by Oncologist onlyThe recommended dosing is 150mg twice daily, taken orally with or without food for 2 years, or until disease recurrence or unacceptable toxicity occurs
6
Abemaciclib 150mg Film Coated TabletsL01XE50-000-T32-03-xxxNoA*Abemaciclib, in combination with endocrine therapy, is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.i. For high-risk stage II and III early breast cancer. High risk defined by clinical and pathological features: either ≥pALN (positive axillary lymph nodes) or 1 – 3 pALN and at least one of the following criteria: tumour size ≥5cm or histological grade 3. ii. To be prescribed by Oncologist onlyThe recommended dosing is 150mg twice daily, taken orally with or without food for 2 years, or until disease recurrence or unacceptable toxicity occurs
7
Abemaciclib 50mg Film Coated TabletsL01XE50-000-T32-01-xxxNoA*Abemaciclib, in combination with endocrine therapy, is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.i. For high-risk stage II and III early breast cancer. High risk defined by clinical and pathological features: either ≥pALN (positive axillary lymph nodes) or 1 – 3 pALN and at least one of the following criteria: tumour size ≥5cm or histological grade 3. ii. To be prescribed by Oncologist onlyThe recommended dosing is 150mg twice daily, taken orally with or without food for 2 years, or until disease recurrence or unacceptable toxicity occurs
8
Abiraterone acetate 250mg tabletL02BX03-000-T10-01-XXXYesA*With prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men.
In combination with prednisone or prednisolone and androgen deprivation herapy (ADT) for the treatment of patients with newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) who may have received up to 3 months of prior ADT.		Prescribing restrictions: i. Those who have progressed on OR failed prior docetaxel chemotherapy ii. Those who are contraindicated or unsuitable for chemotherapy1,000mg once daily
9
Acalabrutinib 100mg Film Coated TabletL01EL02-000-T32-01-xxxNoA*Indicated as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.To be prescribed by Haematologists only100 mg twice daily
10
Acetazolamide 250mg TabletS01EC01-000-T10-01-XXXYesBReduction of intraocular pressure in open-angle glaucoma, secondary glaucoma and peri-operatively in angle-closure glaucomaNone250mg 1-4 times a day, the dosage being titrated according to patient response
11
Acetazolamide 500mg InjectionS01EC01-000-P40-01-XXXYesBReduction of intra-ocular pressure in open-angle glaucoma, secondary glaucoma and peri-operatively in angle-closure glaucomaNoneAdult : 250-1000mg per 24hours, usually in divided doses for amounts over 250mg daily
12
Acetylcysteine 200mg/ml InjectionV03AB23-520-P30-01-XXXYesA*Antidote for paracetamol poisoningNoneDiluted with dextrose 5% and infused IV. Initial, 150 mg/kg IV in 200 ml over 60 minutes, then 50 mg/kg IV in 500 ml over 4 hours, followed by 100 mg/kg IV in 1000 ml over 16 hours. Total dose: 300mg/kg in 20 hour
13
Acetylsalicylic Acid 100 mg & Glycine 45 mg TabletB01AC06-259-T10-01-XXXNoBi) Prevention of myocardial infarct, stroke, vascular occlusion and deep vein thrombosis. ii) Transient ischaemic attacksNone1 tablet daily
14
Acetylsalicylic Acid 150mg Dispersible TabletN02BA01-000-T40-03-XXXYesCInitial treatment of cardiovascular disorders such as angina pectoris and myocardial infarction and for the prevention of cardiovascular events in patients at risk. Other such uses include the treatment and prevention of cerebrovascular disorders such as strokeNone150mg to be taken daily. Dose to be individualised. Use in children under 16 years old is not recommended
15
Acetylsalicylic Acid 300 mg Soluble TabletN02BA01-000-T40-01-XXXYesCInitial treatment of cardiovascular disorders such as angina pectoris and myocardial infarction and for the prevention of cardiovascular events in patients at risk. Other such uses include the treatment and prevention of cerebrovascular disorders such as stroke.None150mg to be taken daily. Use in children under 16 years old is not recommended
16
Acetylsalicylic Acid 75mg Dispersible TabletN02BA01-000-T40-02-XXXYesCInitial treatment of cardiovascular disorders such as angina pectoris and myocardial infarction and for the prevention of cardiovascular events in patients at risk. Other such uses include the treatment and prevention of cerebrovascular disorders such as strokeNoneDose to be individualised. 150mg to be taken daily. Use in children under 16 years old is not recommended
17
Acitretin 10mg CapsuleD05BB02-000-C10-01-XXXNoA*i) Severe form of psoriasis including erythrodermic psoriasis and local or generalized pustular psoriasis. ii) Severe disorders of keratinization, such as -congenital ichthyosis -pityriasis rubra pilaris -Darier's disease -other disorders of keratinization which may be resistant to other therapiesNoneADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted according to response, usually within range 25-50 mg daily for further 6-8 weeks (max: 75 mg daily). In disorders of keratinization, maintenance therapy of less than 20mg/day and should not exceed 50mg/day CHILD: 0.5mg/kg daily occasionally up to 1 mg/kg daily to a max. 35 mg daily for limited periods
18
Acitretin 25 mg CapsuleD05BB02-000-C10-02-XXXNoA*i) Severe form of psoriasis including erythrodermic psoriasis and local or generalized pustular psoriasis. ii) Severe disorders of keratinization, such as -congenital ichthyosis -pityriasis rubra pilaris -Darier's disease -other disorders of keratinization which may be resistant to other therapiesNoneADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted according to response, usually within range 25-50 mg daily for further 6-8 weeks (max: 75 mg daily). In disorders of keratinization, maintenance therapy of less than 20mg/day and should not exceed 50mg/day CHILD: 0.5mg/kg daily occasionally up to 1 mg/kg daily to a max. 35 mg daily for limited periods
19
Acriflavine 0.1% CreamD08AA03-000-G10-01-xxxYesC+Infected skin, lesions, cuts, abrasions, wounds and burns.NoneApply undiluted three times daily to the affected part .
20
Acriflavine 0.1% LotionD08AA03-000-L60-01-XXXYesC+Infected skin, lesions, cuts, abrasions, wounds and burns.NoneApply undiluted three times daily to the affected part .
21
Actinomycin D (Dactinomycin) 500 mcg/ml InjectionL01DA01-110-P40-01-XXXYesAi) For solid tumours ii) Gestational trophoblastic diseaseNonei) ADULT: 500 mcg IV daily for max of 5 days. CHILD: 1.5 mg/m2 once every 3 weeks (if weight less than 10 kg, 50 mcg/kg) ii) 500 mcg IV on Days 2, 4, 6, 8, 10, repeat every 7 - 10 days or 500 mcg IV bolus on Days 1 and 2, repeat every 15 days
22
Acyclovir (Aciclovir) 200mg TabletJ05AB01-000-T10-01-XXXYesA/KKi) Treatment of Herpes simplex & Varicella zoster infections ii) Prophylaxis of Herpes simplex infections in immune-compromised patientsNoneIndication (i) Treatment for Herpes Simplex: ADULT - 200mg 5 times daily; In severely immune-compromised patients: dose can be doubled to 400 mg. CHILD - two years and above should be given adult dosages, infants and children below two years old should be given half the adult dose. Treatment for Varicella Zoster: ADULT - 800mg 5 times daily; CHILD 6 years and over: 800 mg four times daily, 2 - < 6 years: 400 mg four times daily, Under 2 years: 200 mg four times daily. Indication (ii) ADULT - Immune-compromised patients: 200 mg four times daily. Severely immune-compromised patients: dose can be doubled to 400 mg. CHILD - two years and above should be given adult dosages, infants and children below two years old should be given half the adult dose. Dosing is according to Product Information Leaflet.
23
Acyclovir (Aciclovir) 200mg/5 ml SuspensionJ05AB01-000-L80-01-XXXYesA*i) Mucocutaneous Herpes Simplex infection in immunocompromised and AIDS patients ii) Primary and recurrent Varicella Zoster infection in immunocompromised and AIDS patients iii) Severe Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans) vi) Severe zoster infection in paediatrics (eg.Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster)Nonei) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD : less than 2 years, half adult dose; more than 2 years, adult dose. v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD: less than 2 years; 400mg 4 times daily, more than 2 years; 800 mg 4 times daily
24
Acyclovir (Aciclovir) 250mg InjectionJ05AB01-000-P4-001-XXXYesA*i)Treatment of Herpes simplex & Varicella zoster infections ii)Prophylaxis of Herpes simplex infections in immune-compromised patientsNoneADULT: 5 mg/kg by IV infusion 8 hourly for 5 days, doubled to 10mg/kg every 8 hourly in varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for at least 10 days in encephalitis; possibly for 14 - 21 days). NEONATE & INFANT up to 3 months with disseminated herpes simplex: 20mg/kg every 8 hourly for 14 days (21 days in CNS involvement), varicella-zoster 10-20mg/kg every 8 hourly usually for 7 days. CHILD, 3 months - 12 years: Herpes simplex or Varicella Zoster: 250 mg/m2 8 hourly for 5 days, doubled to 500 mg/m2 8 hourly for varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for 10 days in encephalitis)
25
Acyclovir (Aciclovir) 3% Eye OintmentS01AD03-000-G51-01-XXXYesA*Only for the treatment of herpes simplex keratitisNoneApply 1 cm 5 times daily. Continue for at least 3 days after healing
26
Acyclovir (Aciclovir) 5% CreamD06BB03-000-G10-01-XXXNoA*Herpes simplex infections of the skin, including initial and recurrent labial and genital herpes simplex infectionsNoneApply every 4 hours for 5 - 10 days
27
Acyclovir (Aciclovir) 800 mg TabletJ05AB01-000-T10-02-XXXYesA/KKi)Treatment of Herpes simplex & Varicella zoster infections ii)Prophylaxis of Herpes simplex infections in immune-compromised patientsNoneIndication (i) Treatment for Herpes Simplex: ADULT - 200mg 5 times daily; In severely immune-compromised patients: dose can be doubled to 400 mg. CHILD - two years and above should be given adult dosages, infants and children below two years old should be given half the adult dose. Treatment for Varicella Zoster: ADULT - 800mg 5 times daily; CHILD - 6 years and over: 800 mg four times daily, 2 - < 6 years: 400 mg four times daily, Under 2 years: 200 mg four times daily. Indication (ii) ADULT - Immune-compromised patients: 200 mg four times daily. Severely immune-compromised patients: dose can be doubled to 400 mg. CHILD - two years and above should be given adult dosages, infants and children below two years old should be given half the adult dose. Dosing is according to Product Information Leaflet.
28
Adalimumab 40mg InjectionL04AB04-000-P50-01-XXXYesA*i) Third line treatment of: - Severe rheumatoid arthritis - Psoriatic arthritis - For reducing signs and symptoms in patients with active ankylosing spondylitis, after failure of conventional DMARDs or other biologics. ii)Treatment of adults with moderate to severe chronic plaque psoriasis who have not responded to, have contraindication or are unable to tolerate phototherapy and/or systemic therapies including acitretin, methotreaxate and cyclosporine iii) Crohn's Disease a) For treatment of moderately to severely active Crohn's Disease in adult patients who have inadequate response to conventional therapy b) For treatment of moderately to severely active Crohn?s Disease in adult patients who have lost response to or are intolerant to infliximab iv) Ulcerative Colitis - For treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapiesNonei)Severe rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis : Subcutaneous 40 mg every other week ii)Chronic plaque psoriasis : Initial, 80 mg SC, followed by 40 mg SC every other week starting one week after the initial dose iii) & iv) Crohn's disease & Ulcerative colitis: 160mg at week 0 (dose can be administered as four injections in one day or as two injections per day for two consecutive days) and 80mg at week 2. After induction treatment, the recommended maintenance dose is 40mg every other week via subcutaneous injection.
29
Adapalene 0.1% CreamD10AD03-000-G10-01-XXXNoA*Acne vulgaris where comedones, papules and pustules predominate in those sensitive to benzoyl peroxide or topical tretinoin [third line treatment]NoneApply once daily to the affected areas after washing at bedtime
30
Adapalene 0.1% GelD10AD03-000-G30-01-XXXNoA/KKTreatment for acne vulgaris where comedones, papules and pustules predominateNoneApply once daily to the affected areas after washing at bedtime
31
Adenosine 3 mg/ml InjectionC01EB10-000-P30-01-XXXYesBRapid conversion of paroxysmal supraventricular tachycardia to sinus rhythmNoneADULT: Initially: 3 mg given as a rapid IV bolus (over 2 seconds). Second dose: If the first dose does not result in elimination of the supraventricular tachycardia with in 1 or 2 minutes, 6 mg should be given also as a rapid IV bolus. Third dose: If the second dose does not result in elimination of the supraventicular tachycardia with in 1-2 minutes, 12 mg should be given also as a rapid IV bolus
32
Adrenaline Acid Tartrate (Epinephrine) 1 mg/ml InjectionC01CA24-123-P30-01-XXXYesBCardiopulmonary resuscitationNone1 mg by intravenous injection repeated every 3-5 minutes according to response
33
Afatinib Dimaleate 30mg Film-Coated TabletL01XE13-253-T32-02-XXXYesA*First-line monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).i) Adenocarcinoma histology. ii) Patient's ECOG Performance Status 0-1. **To be prescribed by Consultants/Specialists from disciplines of oncology and oncology-trained respiratory physician)**40mg once daily to be taken without food. Maximum dose is 50mg once daily.
34
Afatinib Dimaleate 40mg Film-Coated TabletL01XE13-253-T32-03-XXXYesA*First-line monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).i) Adenocarcinoma histology. ii) Patient's ECOG Performance Status 0-1. **To be prescribed by Consultants/Specialists from disciplines of oncology and oncology-trained respiratory physician)**40mg once daily to be taken without food. Maximum dose is 50mg once daily.
35
Aflibercept 40mg/ml solution for injection (vial)S01LA05-000-P30-01-XXXNoA*i) Treatment of neovascular (wet) age-related macular degeneration (wet AMD) ii) Visual impairment due to diabetic macular edema (DME) iii) Macular Oedema secondary to Retinal Vein Occlusion (branch RVO or central RVO)For all indications: To be used by ophthalmologistsonly. For indication (ii): a) Treatment of naive patients with visual acuity equal or worse than 20/50; or b) Patients with poor response to treatment with ranibizumab. For indication (iii): a) First line for patient not able to comply with monthly ranibizumab injection after initial loading doses b) Second line for patient who are refractory to ranibizumab injectioni) The recommended dose is 2mg aflibercept, equivalent to 0.05mL (50 μL) given as intra-vitreal injection. Aflibercept treatment is initiated with one injection per month for three consecutive doses, followed by one injection every two months. ii) 2 mg aflibercept (equivalent to 50 microliters) administered by intravitreal injection monthly for the first 5 consecutive doses, followed by one injection every 2 months. There is no requirement for monitoring between injections. iii) 2 mg aflibercept (equivalent to 50 microliters) administered by intravitreal injection monthly. The interval between two doses should not be shorter than one month.
36
Agomelatine 25mg TabletN06AX22-000-T10-01-XXXNoA*Major depressionNoneThe recommended dose is 25mg once daily at bedtime, maybe increased to 50mg once daily at bedtime.
37
Albendazole 200mg TabletP02CA03-000-T10-01-XXXYesC+i) Single or mixed infestations of intestinal parasites ii) Strongyloides infectionNonei)Child 12-24months: 200mg as a single dose ii) Adult & Child above 2 years: 400mg as a single dose for 3 consecutive days; Child 12 - 24months: 200mg as a single dose for 3 consecutive days
38
Albendazole 200mg/5 ml SuspensionP02CA03-000-L80-01-XXXYesC+i) Single or mixed infestations of intestinal parasites ii) Strongyloides infectionNonei)Child 12-24months: 200mg as a single dose ii) Adult & Child above 2 years: 400mg as a single dose for 3 consecutive days; Child 12 - 24months: 200mg as a single dose for 3 consecutive days
39
Alcohol 70% SolutionD08AX08-000-L99-01-XXXYesC+Use as antiseptic and disinfectantNoneApply to the skin undiluted or when needed
40
Alectinib 150mg Hard CapsuleL01XE36-110-C11-01-XXXNoA*As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).To be prescribed by Oncologist only600 mg twice daily with food (total daily dose of 1200 mg). Treatment with alectinib should be continued until disease progression or unacceptable toxicity.
41
Alendronate Sodium 70mg and Cholecalciferol 5600 IU TabletM05BB03-972-T10-02-XXXNoA*i) Osteoporosis in postmenopausal women with a history of vertebral fracture and whom oestrogen replacement therapy is contraindicated ii) Male OsteoporosisNone1 tablet once weekly [70mg/5600 IU]. Patient should receive supplemental calcium or vitamin D, if dietary vitamin D inadequate. The tablet should be taken at least half and hour before the first food, beverage, or medication of the day with plain water only. To facilitate delivery to stomach and thus reduce the potential for esophageal irritation, it should only be swallowed upon arising for the day with a full glass of water and patient should not lie down for at least 30 minutes and until after their first food of the day.
42
Alendronate Sodium 70mg TabletM05BA04-520-T10-01-XXXNoA*, A/KKKategori preskriber A*: Osteoporosis (Male) Kategori preskriber A/KK: Indicated for the treatment of osteoporosis in high-risk postmenopausal womenNone70 mg once weekly. Swallow the tablet whole with a full glass of plain water only on an empty stomach at least 30 minutes before breakfast (and any other oral medication); stand or sit upright for at least 30 minutes and do not lie down until after eating breakfast
43
Alfacalcidol 0.25mcg CapsuleA11CC03-000-C10-01-XXXNoA/KKi) Chronic kidney disease mineral bone disorder ii) Osteoporosis iii) Hypoparathyroidism and pseudohypoparathyroidism iv) Rickets and osteomalaciaNoneInitial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily Dosing is individualised based on serum calcium level and according to product insert/protocol
44
Alfacalcidol 1mcg CapsuleA11CC03-000-C10-02-XXXNoA/KKi) Chronic kidney disease mineral bone disorder ii) Osteoporosis iii) Hypoparathyroidism and pseudohypoparathyroidism iv) Rickets and osteomalaciaNoneInitial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily Dosing is individualised based on serum calcium level and according to product insert/protocol
45
Alfacalcidol 2 mcg/ml InjectionA11CC03-000-P30-01-XXXNoA*i) Chronic kidney disease mineral bone disorder ii) Osteoporosis iii) Hypoparathyroidism and pseudohypoparathyroidism iv) Rickets and osteomalaciaNoneInitial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily Dosing is individualised based on serum calcium level and according to product insert/protocol
46
Alfacalcidol 2mcg/ml DropsA11CC03-000-D50-01-XXXNoA*i) Neonatal hypocalcemia ii) Osteoporosis iii) Hypoparathyroidism and pseudohypoparathyroidism iv) Rickets and osteomalaciaNoneNEONATES : 0.1 mcg/kg/day Dosing is individualised based on serum calcium level and according to product insert/protocol
47
Alfentanil HCl 0.5 mg/ml InjectionN01AH02-110-P30-01-XXXNoA*For use as short acting narcotic analgesic in short procedures and day-care surgical proceduresNoneInitial dose: 20 - 40 mcg/kg. Supplemental dose: 15 mcg/kg or infusion 0.5 - 1.0 mcg/kg/min
48
Alfuzosin HCl 10mg TabletG04CA01-110-T10-01-XXXNoA*Treatment of functional symptoms related with benign prostatic hypertrophy (BPH)None10 mg once a day pre bed
49
Alglucosidase alfa 5 mg/ml InjectionA16AB07-000-P40-01-XXXNoA*Infantile-onset Pompe diseaseNone20 mg/kg of body weight administered once every 2 weeks as an intravenous infusion. Monitoring It is suggested that patients be monitored periodically for IgG antibody formation. Patients who experience Infusion-associated reactions suggestive of hypersensitivity may be tested for IgE antibodies to alglucosidase alfa. Treated patients who experience a decrease in benefit despite continued treatment with Alglucosidase Alfa, in whom antibodies are suspected to play a role, may be tested for neutralization of enzyme uptake or activity.
50
Alkaline Nasal DoucheR01A000-999-L50-01-XXXNoBTo remove nasal plugNoneTo be diluted with an equal volume of warm water before use
51
All-Trans Retinoic Acid (Tretinoin) 10 mg CapsuleL01XX14-000-C10-01-XXXYesA*Acute promyelocytic leukaemiaNoneInduction: 45 mg/m2 daily for 30 - 90 days. Maintenance: 45 mg/m2 daily for 2 weeks every 3 months. Renal/or hepatic insufficiency: 25mg/m2 daily for 30-90 days. Refer to protocols
52
Allopurinol 100 mg TabletM04AA01-000-T10-02-XXXYesA/KKi) Frequent and disabling attacks of gouty arthritis (2 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iv) Urate nephropathy. v) Urate nephrolithiasis. vi) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia-Initial dose: 50-100 mg daily. Maintenance: 300-900mg daily (depending on renal function).
53
Allopurinol 300 mg TabletM04AA01-000-T10-01XXXYesA/KKi) Frequent and disabling attacks of gouty arthritis (2 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iv) Urate nephropathy. v) Urate nephrolithiasis. vi) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia-Initial dose: 50-100 mg daily. Maintenance: 300-900mg daily (depending on renal function).
54
Alprazolam 0.25mg TabletN05BA12-000-T10-01-XXXNoA/KKAnxiety disordersNone0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
55
Alprazolam 0.5mg TabletN05BA12-000-T10-02-XXXNoAAnxiety disordersNone0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
56
Alprazolam 1mg TabletN05BA12-000-T10-03-XXXNoAAnxiety disordersNone0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
57
Alprostadil 500 mcg/ml InjectionC01EA01-000-P30-01-XXXNoA*For treatment of congenital heart diseases which are ductus arteriosus dependentNone0.05 - 0.1 mcg/kg/min by continuous IV infusion, then decreased to lowest effective dose
58
Alteplase 50 mg per vial InjectionB01AD02-000-P40-01-XXXYesA*Thrombolytic treatment of acute ischaemic stroke.-0.9 mg/kg (maximum of 90 mg) infused over 60 minutes with 10% of the total dose administered as an initial intravenous bolus. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging technique.
59
Amantadine HCl 100mg CapsuleN04BB01-110-C10-01-XXXNoBParkinson's diseaseNoneInitial dose: 100 mg daily and is increased to 100 mg twice daily (not later than 4 p.m.) after a week. Elderly over 65 years: less than 100 mg or 100 mg at intervals of more than 1 day
60
Amikacin 125 mg/ml InjectionJ01GB06-183-P30-03-XXXYesAInfections due to susceptible organismsNoneADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day
61
Amikacin 250mg/ml InjectionJ01GB06-183-P30-02-XXXYesAInfections due to susceptible organismsNoneADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day
62
Amiloride HCl 5 mg & Hydrochlorothiazide 50 mg TabletC03EA01-900-T10-01-XXXNoBi) Diuretic as an adjunct to the management of oedematous states ii) HypertensionNonei) Initially 1 - 2 tab daily adjusted according to response. Max : 4 tabs daily. ii) 1 -2 tabs daily as a single or divided dose
63
Amino Acids & Glucose with Electrolytes InjectionB05BA10-910-P30-03-XXXNoASource of amino acids, carbohydrate and electrolytes in patients needing IV nutritionNoneDose to be individualised. ADULT usual requirement for amino acid 1-2 g/kg/day, carbohydrate 4-6 g/kg/day
64
Amino Acids InjectionB05BA01-910-P30-01-XXXNoASource of amino acids in patients needing IV nutritionNoneDose to be individualised. ADULT usually 500-2000 ml by IV. ADULT usual requirement for amino acid: 1-2 g/kg/day
65
Amino Acids with Electrolytes InjectionB05BA10-910-P30-02-XXXNoASource of amino acids and electrolytes in patients needing IV nutritionNoneDose to be individualised. ADULT usual requirement for amino acid 1-2 g/kg/day
66
Amino Acids, Glucose and Lipid with Electrolytes InjectionB05BA10-910-P30-01-XXXNoASource of amino acids, carbohydrate, lipid and electrolytes in patients needing IV nutritionNoneDose to be individualised. ADULT: 500 - 2000 ml daily given by IV. ADULT usual requirement for amino acid 1-2 g/kg/ day, carbohydrate 4-6 g/kg/day, lipid 2-3 g/kg/day
67
Amino Acids, Glucose and Lipid without Electrolytes InjectionB05BA10-910-P30-04-XXXNoASource of amino acids and carbohydrate in patients needing IV nutrition.NoneADULT usual requirement for amino acid 1-2 g/kg/ day, carbohydrate 4-6 g/kg/day, lipid 2-3 g/kg/day. Dosing is individualised and according to product insert/protocol.
68
Aminophylline 25mg/ml InjectionR03DA05-000-P30-01-XXXYesBReversible airways obstruction, acute severe brochospasmNoneAdult: Loading dose: 6 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min. Children: 6 months and over (if not previously on theophylline): Loading dose: 6mg/kg. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr. Dosing is individualised and according to product insert/protocol.
69
Amiodarone 200 mg TabletC01BD01-110-T10-01-XXXYesA*ArrhythmiasNone200 mg 3 times daily for 1 week, then reduced to 200 mg twice daily for another week. Maintenance dose, usually 200 mg daily or the minimum required to control the arrhythmia. Dosing is according to product insert / protocol.
70
Amiodarone 50 mg/ml InjectionC01BD01-110-P30-01-XXXYesA*, A/KKCategory A*: i) Arrhythmias ii) Cardiopulmonary resuscitation of shock-resistant ventricular fibrillation in cardiac arrest Category A/KK: Ventricular arrythmia (ventricular tachycardia and ventricular fibrillation)Category A*: None Category A/KK: Use only for emergency cases in health clinic with Medical Officers (MO) upon consultation with Family Medicine Specialist (FMS)i) Initial: 5mg/kg over 20-120minutes Maintenance: 10-20mg/kg/24hr Max. dose: 1.2g/24hr. ii) Initial: 300mg or 5mg/kg rapid Additional 150mg if condition persists. Dosing is according to product insert / protocol.
71
Amisulpride 100mg TabletN05AL05-000-T10-01-XXXNoA*Treatment of psychoses, particularly acute or chronic schizophrenia disorders characterized by positive symptoms(e.g. delusion, hallucinations, thought disorders) and/or negative symptoms(e.g. blunted emotions, emotional and social withdrawal) including when the negative symptoms predominateNonePredominantly negative episodes: 50-300 mg once daily adjusted according to the patient's response. Mixed episodes with positive and negative symptoms: 400-800 mg/day in 2 divided doses adjusted according to the patient's response. Should be taken on an empty stomach (Preferably taken before meals)
72
Amisulpride 400mg TabletN05AL05-000-T10-02-XXXNoA*Treatment of psychoses, particularly acute or chronic schizophrenia disorders characterized by positive symptoms(e.g. delusion, hallucinations, thought disorders) and/or negative symptoms(e.g. blunted emotions, emotional and social withdrawal) including when the negative symptoms predominateNonePredominantly negative episodes: 50-300 mg once daily adjusted according to the patient's response. Mixed episodes with positive and negative symptoms: 400-800 mg/day in 2 divided doses adjusted according to the patient's response. Should be taken on an empty stomach (Preferably taken before meals)
73
Amitriptyline HCl 25 mg TabletN06AA09-110-T10-01-XXXYesBi) Depression ii) Nocturnal enuresis where organic pathology has been excludedNonei) Initial: 25mg 3 times a day in the evening Increase gradually in the late evening or at bedtime if necessary up to a maximum of 150mg per day Hospitalised patient: 100mg per day Increase gradually to 200-300mg per day ii) CHILD 6 YEARS AND UNDER: 10mg at bedtime CHILD OVER 6 YEARS Initial: 10mg at bedtime Increase gradually if necessary up to a maximum of 25mg at bedtime Not recommended for treatment of depression in children under 12 years of age. Dosing is individualised and according to product insert/ protocol.
74
Amlodipine 10 mg and Valsartan 160 mg TabletC09DB01-935-T10-03-XXXNoA/KKEssential hypertension in patients whose blood pressure is not adequately controlled by monotherapyNoneDoses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg
75
Amlodipine 10 mg TabletC08CA01-000-T10-02-XXXYesBHypertensionNone5 mg once daily. Max: 10 mg once daily
76
Amlodipine 5 mg and Valsartan 160 mg TabletC09DB01-935-T10-02-XXXNoA/KKEssential hypertension in patients whose blood pressure is not adequately controlled by monotherapyNoneDoses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg
77
Amlodipine 5 mg TabletC08CA01-000-T10-01-XXXYesBHypertensionNone5 mg once daily. Max: 10 mg once daily
78
Amorolfine 5% Nail LacquerD01AE16-110-L50-01-XXXNoA*Fungal nail infectionsNoneApply to affected nail once or sometimes twice a week after filling and cleansing, allow to dry, treat finger nail for 6 months, toe nail for 9 - 12 months (review at intervals of 3 months)
79
Amoxicillin (Amoxycillin) & Clavulanate 228 mg/5 ml SyrupJ01CR02-961-F21-02-XXXYesA/KKInfections caused by susceptible organismsNoneMild to Moderate infection: 25mg/kg/day (based on Amoxicillin dose) in 2 divided dose. Severe infection: 45mg/kg/day (based on Amoxicillin dose) in 2 divided dose
80
Amoxicillin (Amoxycillin) 1g & Clavulanate 200mg InjectionJ01CR02-961-P40-02-XXXYesAInfections caused by susceptible organisms. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection & osteomyelitisNoneCHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12 years: 30mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8 hourly
81
Amoxicillin (Amoxycillin) 250mg CapsuleJ01CA04-012-C10-01-XXXYesBInfections caused by susceptible strains of gram positive and gram negative organismsNoneADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in divided doses 8 hourly
82
Amoxicillin (Amoxycillin) 250mg/5mL Oral SolutionJ01CA04-012-L80-01-XXXYesBInfections caused by susceptible strains of gram positive and gram negative organismsNoneCHILD less than 10 years: 125 - 250 mg 8 hourly. CHILD less than 20 kg: 20 - 40 mg/kg/day in 3 - 4 divided doses
83
Amoxicillin (Amoxycillin) 500mg & Clavulanate 125mg TabletJ01CR02-961-T10-02-XXXYesA/KKInfections due to beta-lactamase producing strain where amoxicillin alone is not appropriate. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection & osteomyelitisNoneADULT & CHILD more than 12 years: Mild to moderate infections: 625 mg twice daily.
84
Amoxicillin (Amoxycillin) 500mg and Clavulanate 100mg InjectionJ01CR02-961-P40-01-XXXYesAInfections caused by susceptible organisms. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection and osteomyelitisNoneCHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12 years: 30 mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8 hourly
85
Amoxicillin (Amoxycillin) 500mg CapsuleJ01CA04-012-C10-02-XXXYesBInfections caused by susceptible strains of gram positive and gram negative organismsNoneADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in divided doses 8 hourly
86
Amoxicillin (Amoxycillin) Trihydrate 125 mg/5 ml SyrupJ01CA04-012-F10-01-XXXYesBInfections caused by susceptible strains of gram positive and gram negative organismsNoneCHILD less than 10 years: 125 - 250 mg 8 hourly. CHILD less than 20 kg: 20 - 40 mg/kg/day in 3 - 4 divided doses
87
Amphotericin B 50 mg Injection (Conventional)J02AA01-801-P40-01-XXXYesASystemic fungal infectionsNoneADULT: 0.25 mg/kg/day by IV infusion, gradually increase if tolerated to 1 mg/kg/day. Maximum in severe cases: 1.5 mg/kg daily or on alternate days. For neonates, lower doses are recommended
88
Ampicillin Sodium & Sulbactam Sodium 250 mg/5 ml SuspensionJ01CR01-961-F21-01-XXXNoATreatment of susceptible bacterial infectionsNoneADULT: 375-750mg twice daily. CHILDREN (weight < 30kg): 25-50mg/kg/day in two divided doses. For children weighing 30kg and more, follow usual adult dose.
89
Ampicillin Sodium & Sulbactam Sodium 375 mg TabletJ01CR01-961-T10-01-XXXNoA/KKTreatment of susceptible bacterial infectionsNoneADULT: 375-750mg twice daily CHILDREN AND INFANTS: 25-50mg/kg/day in 2 divided doses, if ≥ 30kg use an adult dose
90
Ampicillin Sodium 1g & Sulbactam Sodium 500mg InjectionJ01CR01-961-P40-02-XXXNoATreatment of susceptible bacterial infectionsNoneADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g Sulbactam. CHILD: 150-300 mg/kg/day 6 - 8 hourly. Prophylaxis of surgical infections: 1.5 - 3 g at induction of anaesthesia. May be repeated 6 - 8 hourly. NEONATES: First week of life, 75mg/kg/day in divided doses every 12 hour
91
Ampicillin Sodium 500 mg InjectionJ01CA01-520-P40-01-XXXYesBTreatment of susceptible bacterial infections (non beta-lactamase-producing organisms); meningitisNone250 - 500 mg IM/IV every 4 - 6 hours. Maximum: 400 mg/kg/day. Meningitis: 2 g 6 hourly. CHILD: 150 mg/kg/daily IV in divided doses. Usual children dose less than 10 years, half adult dose
92
Ampicillin Sodium 500mg & Sulbactam Sodium 250mg InjectionJ01CR01-961-P40-01-XXXNoATreatment of susceptible bacterial infectionsNoneADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g Sulbactam per day. CHILD: 150-300mg/kg/day 6 - 8 hourly. Prophylaxis: 1.5 -3 g at induction of anaesthesia. May be repeated 6 - 8 hourly
93
Ampicillin Trihydrate 125 mg/5 ml SuspensionJ01CA01-012-F21-01-XXXYesBTreatment of susceptible bacterial infections (non beta-lactamase-producing organisms)NoneCHILD: 50 - 100 mg/kg/day 4 times daily. Under 1 year: 62.5 - 125 mg 4 times daily, 1 - 10 years: 125 - 250 mg 4 times daily
94
Anastrozole 1 mg TabletL02BG03-000-T10-01-XXXYesA*Hormonal therapy in breast cancer in post-menopausal women if failed /contraindicated with Tamoxifen-1 mg daily
95
Anidulafungin 100mg InjectionJ02AX06-000-P30-01-XXXYesA*Treatment of invasive candidiasis, including candidemia in adults when intolerance or resistance to Amphotericin B or FluconazoleNoneLoading dose of 200 mg on day 1, then 100 mg once daily thereafter for at least 14 days after the last positive culture.
96
Anifrolumab 300mg/2ml Concentrate for Solution for InfusionL04AA51-000-P33-01-xxxNoA*Indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.i) Use is restricted to patients without lupus nephritis or central nervous system (CNS) lupus ii) To be prescribed by Rheumatologists onlyThe recommended dose is 300 mg, administered as an intravenous infusion over a 30-minute period, every 4 weeks. In patients with a history of infusion-related reactions, premedication (e.g., an antihistamine) may be administered before the infusion of anifrolumab.
97
Anti Rhd Immunoglobulin InjectionJ06BB01-000-P30-01-XXXYesBPrevention of Rh(D) sensitisation to Rh(D)-negative woman: i) Pregnancy/delivery of Rh(D)-positive infant ii) Abortion/threatened abortion, ectopic pregnancy or hydatidiform mole iii) Transplacental haemorrhage resulting from antepartum haemorrhage, amniocentesis, chorionic biopsy or obstetric manipulative procedures e.g. external version or abdominal trauma-i) Antenatal prophylaxis: According to general recommendations, currently administered doses range from 50 – 330 micrograms or 250 - 1650 IU. For specific details, please refer to product's package insert. ii) Postnatal prophylaxis: According to general recommendations, currently administered doses range from 100 – 300 micrograms or 500 – 1500 IU. For specific details, please refer to product's package insert.
98
Antilymphocyte/Antithymocyte Immunoglobulin (from Horse) InjectionL04AA03-000-P30-01-XXXNoA*i) To be used when conventional anti-rejection therapy is not successful ii) Treatment of aplastic anaemia not responding to oxymethalone after 3 months, in which there is persistent pancytopenia with repeated attacks of septicaemia and bleeding. iii) Severe aplastic anaemia with the following parameters: a) Granulocyte less than 0.5x109/L b) Platelet less than 20x109/L c) Reticulocyte less than 20x109/L iv) As a conditioning regime prior to transplant. v) Graft-versus-host disease treatment-10 - 30 mg/kg body weight daily. Slow IV infusion (over at least 4 hours) diluted in 250 - 500 ml Normal Saline. For Graft versus host disease treatment:40 mg/kg/day
99
Antirabies Immunoglobulin InjectionJ06BB05-000-P30-01-XXXYesBTreatment of rabies, post-exposureNoneHuman rabies immunoglobulin: 20 iu/kg; half by IM and half by infiltration around the wound. Equine rabies immunoglobulin: 40iu/kg of body weigth in adults and children. Note: Please refer to package insert for recommendations by the manufacturer.
100
Antithymocyte Immunoglobulin (from rabbit) InjectionL04AA04-000-P30-01-XXXYesA*i)Prophylaxis of acute graft rejection ii)Treatment of acute graft rejection iii)Prophylaxis of acute and chronic graft versus host disease iv)Treatment of steroid-resistant, acute graft versus host disease v)Treatment of aplastic anemia-i)1.0 - 1.5 mg/kg/day for 2 - 9 days after transplantation of a kidney, pancreas or liver, for 2 - 5 days after heart transplantation ii)1.5 mg/kg/day for 3 - 14 days iii)2.5 - 5.0 mg/kg/day for 4 days iv)2.5 - 5.0 mg/kg/day for 5 days v)2.5 - 3.5 mg/kg/day for 5 days